Craig Hallum Begins Coverage on MediWound (NASDAQ:MDWD)

Craig Hallum assumed coverage on shares of MediWound (NASDAQ:MDWD) in a report issued on Friday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $39.00 price target on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of MediWound in a research note on Friday, January 10th.

MediWound Price Performance

NASDAQ:MDWD opened at $16.60 on Friday. The firm has a market capitalization of $179.05 million, a price-to-earnings ratio of -5.72 and a beta of 0.81. MediWound has a 1 year low of $12.78 and a 1 year high of $24.00. The business has a 50 day simple moving average of $18.18 and a 200-day simple moving average of $17.71.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the business earned ($0.24) earnings per share. As a group, analysts expect that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

Hedge funds and other institutional investors have recently modified their holdings of the business. ARK Investment Management LLC purchased a new stake in shares of MediWound in the third quarter worth approximately $1,806,000. State Street Corp raised its holdings in shares of MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after buying an additional 45,529 shares during the period. Barclays PLC raised its holdings in shares of MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 8,449 shares during the period. Rosalind Advisors Inc. raised its holdings in shares of MediWound by 22.3% in the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after buying an additional 114,560 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of MediWound in the third quarter worth approximately $212,000. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.